| 1 | Golimumab | Adalimumab, etanercept, golimumab or infliximab 45件: Adalimumab, etanercept, golimumab or infliximab; Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Diagnostic test: antibodies to golimumab; Diagnostic test: golimumab trough levels; Exposure to golimumab; Golimumab; Golimumab (cnto 148); Golimumab (glm); Golimumab (gol); Golimumab (optimization); Golimumab 1 mg per kg; Golimumab 100 mg; Golimumab 100 mg injections; Golimumab 2 mg per kg; Golimumab 2 mg/kg iv; Golimumab 200 mg; Golimumab 4 mg per kg; Golimumab 400 mg; Golimumab 50 mg; Golimumab 50 mg in patients <80 kg and golimumab 100 mg in patients >80 kg; Golimumab 50 mg injections; Golimumab 50 mg sc; Golimumab dose 1; Golimumab dose 2; Golimumab final vialed product (fvp); Golimumab injection; Golimumab intravenous; Golimumab intravenous (iv); Golimumab liquid in prefilled pen; Golimumab liquid in prefilled pen or prefilled syringe; Golimumab liquid in prefilled syringe; Golimumab liquid in vial; Golimumab pre-filled syringe; Golimumab prefilled pen; Golimumab prefilled pen or prefilled syringe; Golimumab prefilled syringe; Golimumab treatment optimization.; Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab; Iv golimumab; Prefilled syringe delivery of golimumab; Sc golimumab; Simponi (golimumab); Simponi® (golimumab); Smartject device delivery of golimumab; Tumor necrosis factor inhibitor (etanercept, infliximab, adalimumab, and golimumab); | 1件: D04358 D04358 💬 |
1件: TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications 65件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
046 6件: 46, 56, 84, 96, 97, 271 💬 |